Mathematical modeling of the synergetic effect between radiotherapy and immunotherapy
Yixun Xing1,2, Casey Moore3, Debabrata Saha3
1Medical Artificial Intelligence and Automation Laboratory, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Mathematical Biosciences and Engineering : MBE
|April 29, 2025
Summary
Personalized ultra-fractionated stereotactic adaptive radiation (PULSAR) therapy enhances tumor control by optimizing radiotherapy and immunotherapy timing. Longer intervals between radiation pulses significantly improve treatment outcomes, as demonstrated by our predictive model.
Area of Science:
- Oncology
- Radiation Oncology
- Immunology
Background:
- Radiotherapy and immunotherapy synergy is crucial for improved tumor control.
- Personalized ultra-fractionated stereotactic adaptive radiation (PULSAR) therapy explores radiation timing's impact.
- Understanding temporal dynamics is key to optimizing combined treatments.
Purpose of the Study:
- Investigate the mechanisms of synergy between radiotherapy and immunotherapy.
- Evaluate the novel PULSAR therapy approach focusing on radiation timing.
- Develop a quantitative model linking radiation therapy and immunotherapy.
Main Methods:
- Developed a discrete-time model using difference equations based on small-animal radiation studies.
- Incorporated T cell migration and infiltration dynamics within the tumor microenvironment.
- Estimated model parameters using simulated annealing and validated with test data.
Main Results:
- The model accurately predicted tumor control with a root mean square error of 287 mm³.
- Replicated the PULSAR effect, showing longer intervals between radiation pulses enhance tumor control with immunotherapy.
- Observed significantly improved tumor responses in mice receiving immunotherapy with radiation pulses at ten-day intervals.
Conclusions:
- Treatment timing is critical for maximizing radiotherapy and immunotherapy synergy.
- The developed in-silico model can aid in designing personalized radiation therapy trials.
- Findings highlight the potential of optimized treatment scheduling for individualized cancer care.


